- Home
- TYRA vs MYI Comparison
TYRA vs MYI Comparison
Compare TYRA & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- MYI
- Stock Information
- Founded
- TYRA 2018
- MYI 1992
- Country
- TYRA United States
- MYI United States
- Employees
- TYRA N/A
- MYI N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- MYI Investment Bankers/Brokers/Service
- Sector
- TYRA Health Care
- MYI Finance
- Exchange
- TYRA Nasdaq
- MYI Nasdaq
- Market Cap
- TYRA 812.7M
- MYI 794.9M
- IPO Year
- TYRA 2021
- MYI N/A
- Fundamental
- Price
- TYRA $15.36
- MYI $11.29
- Analyst Decision
- TYRA Strong Buy
- MYI
- Analyst Count
- TYRA 5
- MYI 0
- Target Price
- TYRA $31.00
- MYI N/A
- AVG Volume (30 Days)
- TYRA 599.6K
- MYI 256.7K
- Earning Date
- TYRA 11-07-2024
- MYI 01-01-0001
- Dividend Yield
- TYRA N/A
- MYI 4.81%
- EPS Growth
- TYRA N/A
- MYI N/A
- EPS
- TYRA N/A
- MYI N/A
- Revenue
- TYRA N/A
- MYI N/A
- Revenue This Year
- TYRA N/A
- MYI N/A
- Revenue Next Year
- TYRA N/A
- MYI N/A
- P/E Ratio
- TYRA N/A
- MYI N/A
- Revenue Growth
- TYRA N/A
- MYI N/A
- 52 Week Low
- TYRA $10.60
- MYI $9.32
- 52 Week High
- TYRA $29.60
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- TYRA 34.38
- MYI 41.26
- Support Level
- TYRA $15.04
- MYI $11.28
- Resistance Level
- TYRA $16.51
- MYI $11.41
- Average True Range (ATR)
- TYRA 0.94
- MYI 0.10
- MACD
- TYRA 0.04
- MYI 0.02
- Stochastic Oscillator
- TYRA 11.68
- MYI 45.95
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a diversified, closed-ended investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.